Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.37 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.37 |
| ▸ | NOS1 | P29475 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22968567 | 0.86 | KDM4E (0.41) | KDM4ETAS1R3TAS1R1NOS1MEN1 | |
| SCHEMBL22968403 | 0.83 | KDM4E (0.47) | KDM4ETAS1R3TAS1R1NOS1MEN1 | |
| SCHEMBL25968241 | 0.83 | KDM4E (0.41) | KDM4ETAS1R3TAS1R1MEN1TSHR | |
| SCHEMBL22883220 | 0.77 | KDM4E (0.44) | KDM4ETAS1R3TAS1R1MEN1TSHR | |
| SCHEMBL20154875 | 0.77 | TAS1R3 (0.52) | KDM4ETAS1R3TAS1R1 | |
| SCHEMBL20154876 | 0.77 | TAS1R3 (0.52) | KDM4ETAS1R3TAS1R1 | |
| SCHEMBL19662703 | 0.75 | KDM4E (0.61) | KDM4ETAS1R3TAS1R1MEN1TSHR | |
| SCHEMBL18671304 | 0.75 | KDM4E (0.61) | KDM4ETAS1R3TAS1R1MEN1TSHR | |
| SCHEMBL3821420 | 0.75 | KDM4E (0.61) | KDM4ETAS1R3TAS1R1MEN1TSHR | |
| SCHEMBL3821424 | 0.75 | KDM4E (0.61) | KDM4ETAS1R3TAS1R1MEN1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10793859-B2 | Modified oligonucleotides and methods of use | Janssen Biopharma, Inc. (US) | 2020-10-06 | — | — | US | disclosed |
| US-20180135054-A1 | MODIFIED OLIGONUCLEOTIDES AND METHODS OF USE | ALIOS BIOPHARMA, INC. (US) | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10793859-B2 | Modified oligonucleotides and methods of use | NSUN2, ADAR, POLM | KDM4E 2928/4885TAS1R3 4579/4885TAS1R1 4780/4885 |
| US-20180135054-A1 | MODIFIED OLIGONUCLEOTIDES AND METHODS OF USE | NSUN2, ADAR, POLM | KDM4E 2928/4885TAS1R3 4579/4885TAS1R1 4780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.